Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kobayashi Kako Ditches Turnaround Plan with Manufacturing Transfer to Sawai
Embattled generic maker Kobayashi Kako has given up on rebuilding itself from a high-profile GMP scandal that has rattled the industry since late last year, with a decision to transfer its manufacturing facilities and staffers to Big 3 player Sawai…
To read the full story
Related Article
- Kobayashi Kako to Withdraw Marketing License on April 1
March 23, 2023
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
- 400 Kobayashi Kako Staffers Move to Trust Pharmatech
April 4, 2022
- Kobayashi Kako Manufacturing Unit Now Under Sawai; 170 Staffers Remain for Compensation, Drug Handover
April 1, 2022
- Sawai to Acquire Kobayashi Kako’s Manufacturing Sites, Staffers
December 3, 2021
BUSINESS
- Teijin, ASKA Hook Up on Gynecology Drug Discovery
February 18, 2026
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Rakuten to Launch Japan PI of RM-0256 Photoimmunotherapy in April-June
February 17, 2026
- Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…